Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07635316 · ClinicalTrials.gov registry record
A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- 4,023
- Enrollment target
NCT07635316: Recruiting study, sponsored by Novartis Pharmaceuticals.
NCT07635316 is a clinical trial that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 4,023 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07635316 is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- 4,023 participants
- Enrollment target
Study Summary
This study aims to characterize current treatment patterns and clinical outcomes among newly diagnosed GEP-NET patients in the United States using open-source Longitudinal Prescription Claims (LRx) and Patient Centric Medical Claims (Dx) databases supplemented with mortality data.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,023 participants |
| Start Date | 2026-06-12 |
| Est. Completion | 2027-02-25 |
What NCT07635316 shows while recruiting
NCT07635316 is an observational study that tracks outcomes without assigning an intervention. Its 4,023 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT07635316 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07635316 about?
NCT07635316 is a clinical study titled "A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients". This study aims to characterize current treatment patterns and clinical outcomes among newly diagnosed GEP-NET patients in the United States using open-source Longitudinal Prescription Claims (LRx) and Patient Centric Medical Claims (Dx) databases supplemented with mortality data.
What is the current status of trial NCT07635316?
This trial is currently recruiting. The enrollment target is 4,023 participants. The study started on 2026-06-12. Estimated completion is 2027-02-25.
Who is sponsoring clinical trial NCT07635316?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00227253 · 4,000 participants
Chromosome 18 Clinical Research Center
- NCT00811148 · 4,000 participants
Florida Center for Brain Tumor Research
- NCT00897117 · 4,000 participants
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
- NCT00899301 · 4,000 participants
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI